NCT01217229 - Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 3, 2011

Primary Completion Date

April 26, 2012

Study Completion Date

April 26, 2012

Conditions

Hodgkin Lymphoma

Interventions

DRUG

PLX3397

Capsules administered once or twice daily, continuous dosing. Subjects will begin with 900 mg/day, but should safety data allow in our PLX108-01 study, subject may dose at 1200 mg/day.

Trial Locations (6)

10065

Memorial Sloan-Kettering Cancer Center, New York

55905

Mayo Clinic, Rochester

60611

Northwestern University, The Robert H Lurie Comprehensive Cancer Center, Chicago

68198

Nebraska Medical Center, Omaha

77030

MD Anderson Cancer Center, Houston

90095

UCLA Jonsson Comprehensive Cancer Center, Los Angeles